Aptamer 学术简报 — cancer — 2026-10-08

自动生成 by RBTX Aptamer Tracker v0.1。 子主题 cancer：近 14 天 56 篇命中（aptamer 池 207 篇）。

评分公式：composite = 0.45×log(IF) + 0.35×log(cites_velocity) + 0.10×social + 0.10×recency_bonus；满分 100。

#1 [22.5] Synergistic MIP-aptamer dual-recognition on silver-decorated sulfur-doped graphene quantum dots (S-GQDs@Ag) nanohybrids for ultra-sensitive impedimetric carcinoembryonic antigen detection.

The clinical utility of Carcinoembryonic Antigen (CEA) as a cornerstone biomarker for oncological monitoring is frequently hindered by the limitations of traditional immunoassays, including high costs, specialized storage requirements, and complex procedural workflows. To address these challenges, we report the development of a high-performance ...

#2 [14.2] Acid-Activatable Rolling Circle Replication-Based Nucleic Acid Nano-Prodrug for Combined Gene Therapy of Pancreatic Cancer.

Nucleic acid-based gene therapeutics hold great potential for precisely treating pancreatic ductal adenocarcinoma (PDAC), yet their clinical translation remains challenged by the lack of efficient delivery platforms capable of simultaneously minimizing payload leakage, intrinsic toxicity, and immunogenicity. Herein, we report an acid-activatable...

#3 [14.0] Ultrasensitive Electrochemiluminescence Aptasensor With DNA Nanotetrahedron Amplification for Multilevel Detection of cTnI From Cells to Patients.

Accurate detection of myocardial injury (MI) biomarkers for assessing anticancer drug-induced cardiotoxicity has long been constrained by insufficient capture efficiency and limited assay sensitivity. To address this challenge, we developed an electrochemiluminescence (ECL) aptasensor for the detection of cardiac troponin I (cTnI) based on a two...

#4 [12.9] A dual-factor-gated DNA nanomachine enables spatially controlled microRNA imaging with improved tumor specificity

#5 [12.5] Bifunctional Nanozymes for Synergistic Treatment by Boosting Oxidative Stress and Regulating the Protein Kinase B Pathway.

Chemoresistance and dose-limiting toxicity remain major challenges in cancer chemotherapy, largely driven by aberrant activation of the protein kinase B (AKT) survival pathway. Although small-molecule AKT inhibitors can enhance chemosensitivity, their systemic activity frequently disrupts normal metabolic processes and causes severe side effects...

#6 [12.5] Structural DNA nanotechnology-guided spatially-ordered arrangement of aptamers on natural killer cells for solid tumor immunotherapy

#7 [12.0] Portable CRISPR/Cas12a-Based Aptasensor System for Point-of-Care Detection of Cytokine Tumor Necrosis Factor-Alpha (TNF-α).

Tumor necrosis factor-α (TNF-α) is an important inflammatory cytokine whose rapid and quantitative detection is essential for disease diagnosis and monitoring. However, conventional methods are often limited by bulky instrumentation and are not well suited for analysis in complex biological environments. Herein, a portable CRISPR/Cas12a-based ap...

#8 [11.8] Aptamer-based discovery of MARK2 as a potential biomarker for targeted imaging and exosome detection of metastatic colorectal cancer.

Metastatic colorectal cancer (CRC) has a high recurrence rate, rapid progression and poor prognosis. Therefore, the discovery of metastatic related biomarkers is crucial for early diagnosis and treatment. Aptamer W14 was previously developed through cell-systematic evolution of ligands by exponential enrichment (SELEX), which could specifically ...

#9 [11.8] A trifunctional bio-inspired hydrogel-integrated biosensor: Capture substrate, sensing interface, and quasi-solid-state electrolyte for tumor-derived extracellular vesicles detection

Extracellular vesicles (EVs) are key mediators of intercellular communication and promising biomarkers for cancer metastasis. However, the clinical EVs detection is limited by the poor isolation efficiency and insufficient specificity. To overcome these critical challenges, this work presented a mussel-inspired PAGTA-Ca2+ hydrogel-integrated ele...

#10 [11.7] Advances in Aptamer Drug Delivery Systems for Treatment of Glioblastoma.

Therapeutic strategies for glioblastoma have progressed considerably over recent decades. Despite the development of new biomedical technologies and advances in our understanding of physiology and disease progression, effective drug delivery to brain cancer remains a significant challenge. The challenge is delivering therapeutics to the correct ...

Methodology